Navivo Capital

Navivo Capital is an early-stage venture firm with a website and LinkedIn presence consistent with a small European or US emerging manager, with limited published thesis or check-size data. Without disclosure, the most honest read is a generalist seed-stage investor with selective healthcare exposure rather than a dedicated healthcare fund. Healthcare exposure is plausibly opportunistic and most likely to appear in digital health, healthtech, and AI-native consumer health categories where the company is fundamentally a software business. AI focus is plausibly real and applied, in line with the broader emerging-manager pattern. Without disclosed stage or check data, anchor expectations to typical seed norms: pre-seed and seed checks in the EUR 100K to EUR 750K range, often co-investing alongside other small seed funds rather than leading priced rounds. This is the wrong door for capital-intensive therapeutics, devices, or hospital enterprise software where specialist healthcare expertise is the unlock. It is a plausible co-investor for early healthcare software founders who already have a credible lead and want additional thesis-aligned capital. Entry path is the website contact and direct LinkedIn outreach to the principals; warm introductions through shared seed networks materially raise reply rates. Founders should be specific about how the firm fits the round’s syndicate strategy and avoid generic decks; emerging managers reward sharp, narrow asks more reliably than broad fundraising pitches.